Neoadjuvant therapy of BRCA1-driven ovarian cancer by combination of cisplatin, mitomycin C and doxorubicin

Neoadjuvant therapy of BRCA1-driven ovarian cancer by combination of cisplatin, mitomycin C and doxorubicin

Abstract Background Cisplatin, mitomycin C and anthracyclines demonstrate high activity in BRCA1-deficient tumors. This study aimed to evaluate the efficacy of the triplet combination of these drugs in BRCA1-driven high-grade serous ovarian carcinomas (HGSOCs). Methods Ten HGSOC patients with germ-l...

Full description

Bibliographic Details
Main Authors: Tatiana V. Gorodnova, Anna P. Sokolenko, Khristina B. Kotiv, Tatiana N. Sokolova, Alexandr O. Ivantsov, Konstantin D. Guseynov, Ekaterina A. Nekrasova, Olga A. Smirnova, Igor V. Berlev, Evgeny N. Imyanitov
Format: Article
Language:English
Published: BMC 2021-02-01
Series:Hereditary Cancer in Clinical Practice
Subjects:
Ovarian cancer
BRCA1
Neoadjuvant chemotherapy
Cisplatin
Mitomycin C
Doxorubicin
Online Access:https://doi.org/10.1186/s13053-021-00173-2

Internet

https://doi.org/10.1186/s13053-021-00173-2

Similar Items